Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
3.300
-0.460 (-12.23%)
Oct 30, 2025, 12:48 PM EDT - Market open
CELZ Revenue
Creative Medical Technology Holdings had revenue of $6.00K in the twelve months ending June 30, 2025, down -64.71% year-over-year. In the year 2024, Creative Medical Technology Holdings had annual revenue of $11.00K with 22.22% growth.
Revenue (ttm)
$6.00K
Revenue Growth
-64.71%
P/S Ratio
1,617.13
Revenue / Employee
$1,500
Employees
4
Market Cap
8.52M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.00K | 2.00K | 22.22% |
| Dec 31, 2023 | 9.00K | -79.60K | -89.84% |
| Dec 31, 2022 | 88.60K | 846.00 | 0.96% |
| Dec 31, 2021 | 87.75K | -76.75K | -46.65% |
| Dec 31, 2020 | 164.50K | -1.00K | -0.60% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
CELZ News
- 3 hours ago - Creative Medical Technology Holdings, Inc. Ignites Next-Gen Regenerative BioDefense Initiative for U.S. Veterans Exposed to Burn Pits - GlobeNewsWire
- 1 day ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.2 Million Gross Proceeds - GlobeNewsWire
- 3 days ago - Creative Medical Technology Holdings Issues Letter to Shareholders - GlobeNewsWire
- 23 days ago - Creative Medical Technology Holdings Congratulates 2025 Nobel Laureates for Regulatory T Cell Breakthroughs - GlobeNewsWire
- 3 months ago - Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells - GlobeNewsWire
- 3 months ago - Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling - GlobeNewsWire
- 8 months ago - Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - GlobeNewsWire
- 8 months ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds - GlobeNewsWire